Single-Use: Game-Changing Technology for the Biopharmaceutical Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Single-Use: Game-Changing Technology for the Biopharmaceutical Industry


Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 41
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Single-Use Technology—From Evolution to Revolution

Single-use technologies continue to evolve rapidly as more biopharmaceutical companies embrace the concept and start implementing single-use systems in their bioprocesses.

The technical and economic benefits of single-use technologies are well known and the biotechnology industry is broadening its adoption into all bioprocess steps in cell culture, downstream processing and final fill and finish. Although the idea of single use is not new and has become standard practice for filter capsules and storage bags, modern single-use processes are more complex and comprise an integrated production concept in new facilities or the replacement of stainless steel in existing ones. Single-use bioreactors, for example, didn’t exist 20 years ago, and the technology has gone from evolution to revolution in less than two decades.

The growing usage of single-use bags in all crucial process steps of commercial production of biological drugs drives the need for improved quality, robustness and assurance of supply, more robust change control and more robust business continuity. To meet these challenges, single-use suppliers need to partner with resin and film suppliers, establish the full control of their process from the resin to the final product and build production capacity with redundant equipment in multiple locations.

Pharmaceutical Technology Europe
25th Anniversary Issue


Single-Use Systems: Enabling the Future of Biologics Manufacturing

Trends in Single-Use Biomanufacturing

For biopharmaceutical manufacturers, capacity adaptation is crucial. If demand suddenly increases and the required product cannot be made in the right quantities, a company is not just facing a loss of short-term sales, but long-term market share as well. Another challenge is technology transfer in biopharmaceutical manufacturing is often moved several thousand miles away. The future is about “smart process transfer” and thinking carefully about what technologies are put into the pilot plant. It can have a huge impact on process transfers later on.

With the number of biotech drugs in clinical trials expected to increase, companies will need to efficiently manage product changeovers and reliably obtain materials from trustworthy sources. This is a challenge for the supplier as well.

Single use demands greater levels of commitment as manufacturers increasingly depend on their technology providers: a completely different assurance of supply concept is essential.

In Asia, some of the first single-use facilities are already operating, but this is just the beginning. To further secure the future implementation of single-use processing, an international supplier must ensure the consistent quality of materials, fully understand and control the production process, and guarantee a sustainable product supply chain for many years.

It’s a great time to look back at the successful implementation of single-use technologies and, at the same time, look forward to new challenges and new solutions. The success of new biopharmaceutical drugs also relies on innovative solutions that suppliers have to offer to the pharmaceutical industry.

Stefan Schlack
Stefan Schlack

About the Author
Stefan Schlack, Sartorius Stedim Biotech

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here